

Pneumomune-Re Rhodococcus Equi Antibody

Intended use: The prevention or reduction in severity of Rhodococcus equi foal pneumonia by prophylactic treatment. This product is not intended to treat R. equi pneumonia once clinical signs appear.



Dose and Route of Administration:

For intravenous use as an aid in the prevention of pneumonia associated with Rhodococcus equi infection in the equine neonate. A single 1000ml dose given to foals (average weight of 119lbs) within the first 24 hours of life should reduce the incidence of Rhodococcus equi foal pneumonia by 40%. A second dose administered at 3 weeks of age may further reduce the incidence of this disease. In a field trial, foals experiencing failure of passive transfer of maternal antibodies (FPT) i.e. IgG <800mg/dl had a higher incidence of disease than non FPT foals treated with the product. In endemic areas, if exposure and environmental conditions favoring exposure are present, further doses may be necessary for foals up to sixteen (16) weeks of age.

CLINICAL RESULTS

58% reduction in the incidence of R. equi pneumonia when all foals were given two doses of **Pneumomune-Re Rhodococcus Equi Antibody** in the first month of life.

The results are a comparison between the 2001 incidence and the 2000 incidence on a large Florida thoroughbred farm. In 2000, 12/68 plasma treated animals (incidence 17.7%) and 24/81 untreated controls (incidence 29.6%) were diagnosed with R. equi pneumonia.

In 2001 all animals on the farm were treated with no controls and the incidence of R. equi pneumonia was 17/229 or 7.4%. The 2001 year's incidence of 7.4% is 58% reduction from the 2000 year's incidence of 17.7% in the treated animals.